Urea Cycle Disorders Clinical Trial
Official title:
Prospective, Open Label, Multicenter, Efficacy and Safety Study of Several Infusions of HepaStem in Urea Cycle Disorders Paediatric Patients
NCT number | NCT02489292 |
Other study ID # | HEP002 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | October 2014 |
Est. completion date | March 2017 |
Verified date | October 2020 |
Source | Promethera Biosciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the study is to assess the efficacy of HepaStem treatment in paediatric patients suffering from urea cycle disorders.
Status | Completed |
Enrollment | 5 |
Est. completion date | March 2017 |
Est. primary completion date | March 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 12 Years |
Eligibility | Main Inclusion Criteria: - Paediatric patients < 12 years prior to infusion - Patient presents with UCD - Patient shows patency of the portal vein and branches, with normal flow velocity as confirmed by Doppler US and accessibility of the portal vein and /or affluants. Main Exclusion Criteria: - Patient has mild disease severity, easily controlled under standard of care therapy, with no recurrent metabolic crises. - Patient is registered on a liver transplant waiting list or is scheduled for living donor liver transplantation before the end of the study. - Patient presents acute liver failure. - Patient presents clinical or radiological evidence of liver cirrhosis. - Patient presents or has a history of hepatic or extrahepatic malignancy. - Patient has a known clinically significant cardiac malformation. - Patient has a personal history of venous thrombosis, or has a clinically significant abnormal value for protein S, protein C, anti-thrombin III, and /or activated Protein C Resistance (aPCR) at screening. In case of known family history, a complete coagulation work-up should be performed. In all above described cases, results need to be discussed with PB before enrolling the patient in the study. - Patient had or has a renal insufficiency treated by dialysis. |
Country | Name | City | State |
---|---|---|---|
Belgium | Cliniques Universitaires Saint-Luc | Brussels | |
France | Hôpital Jeanne de Flandre, CHRU Lille | Lille | |
Poland | Instytut - Pomnik Centrum Zdrowia Dziecka | Warszawa | |
Spain | Hospital Materno Infatil de Badajoz | Badajoz | |
Spain | Hospital Universitari Vall d'Hebron de Barcelona | Barcelona | |
Spain | Hospital Materno Infantil de Málaga | Málaga |
Lead Sponsor | Collaborator |
---|---|
Promethera Biosciences |
Belgium, France, Poland, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy as determined by de novo ureagenesis (C13 tracer method) | at 6m post-first infusion day | ||
Secondary | Efficacy as determined by de novo ureagenesis (C13 tracer method) | at 3, 9 and 12 months post-first infusion day | ||
Secondary | Efficacy as determined by Ammonia (NH3) values | up to 12 months post-first infusion day | ||
Secondary | Efficacy as determined by amino acids in plasma | up to 12 months post-first infusion day | ||
Secondary | Efficacy as determined by report of metabolic decompensations | up to 12 months post-first infusion day | ||
Secondary | Efficacy as determined by report on actual supportive treatment, adjustment of protein restriction and amino acids supplements | up to 12 months post-first infusion day | ||
Secondary | Efficacy as determined report on behavior, cognitive skills and health-related quality-of-life indicators | up to 12 months post-first infusion day | ||
Secondary | To evaluate the safety during the year following HepaStem infusions (composite) | Safety evaluation in terms of (1) clinical status, (2) portal vein hemodynamics, (3) morphology of the liver, bile ducts and portal system, (4) laboratory tests, (5) De novo detection of donor-specific circulating anti-human leukocyte antigen (HLA) antibodies, and/or other immune-related markers, (6) serious adverse events and clinically significant adverse events related to HepaStem, technical intervention, and concomitant treatments. | up to 12 months post-first infusion day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02252770 -
Nitric Oxide Supplementation in Argininosuccinic Aciduria
|
N/A | |
Completed |
NCT01002469 -
Study to Evaluate 13 C Isotope Ratio Measurement for Urea Cycle Capacity Assessment
|
N/A | |
Completed |
NCT00986895 -
A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group
|
Phase 1 | |
Completed |
NCT01257737 -
To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)
|
Phase 4 | |
Recruiting |
NCT05671666 -
Ureagenesis Analysis in Healthy Subjects and in Urea Cycle Disorder Patients
|
N/A | |
Completed |
NCT02311283 -
Pilot Study: Urea Cycle Disorders Practice Patterns and Outcomes Assessment
|
N/A | |
Completed |
NCT00992459 -
Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders
|
Phase 3 | |
Completed |
NCT00551200 -
Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders
|
Phase 2 | |
Completed |
NCT00947297 -
Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)
|
Phase 3 | |
Completed |
NCT02740153 -
PCORI Urea Cycle Disorder Study
|
||
Completed |
NCT02051049 -
Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001)
|
||
Completed |
NCT01765283 -
Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN)
|
Phase 1/Phase 2 | |
Completed |
NCT00947544 -
Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders
|
Phase 2 | |
Completed |
NCT01347073 -
Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)
|
Phase 3 | |
Completed |
NCT00718627 -
Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders
|
Phase 2 | |
Completed |
NCT03797131 -
Clinical Food Study to Evaluate the Effect of KB195 on Gut Nitrogen Metabolism in Patients With Urea Cycle Disorders
|
N/A | |
Completed |
NCT01549015 -
Study in Healthy Subjects, Patients With Urea Cycle Disorders (UCD) and Carriers of UCD Mutations to Evaluate Urea Cycle Function
|
N/A | |
Terminated |
NCT01541722 -
Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders
|
N/A | |
Completed |
NCT00345605 -
Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder
|
Phase 2 | |
Recruiting |
NCT00237315 -
Longitudinal Study of Urea Cycle Disorders
|